IMMX

Immix Biopharma, Inc.
CAPPED RATING

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma, Inc. (IMMX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (D). The rating has held at C for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D
Factor Score 1.3 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -9.1
EV / EBITDA -9.4
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -20.7%
Price Return 12M 167.3%
Catalyst Signal 0.00
Market Cap $717.9M
TTM Revenue N/A
Price / Sales N/A
ROE -34.2%

Historical Factor Score Progression

Held C for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) D (1.3) C+ (2.7) C (2.4) C+ (2.6) C (2.3)
2026-11-05 C+ (2.5) D (1.3) C+ (2.7) C+ (2.7) C+ (2.7) C (2.4)
2026-10-29 C+ (2.5) D (1.3) C+ (2.7) B- (3.1) C+ (2.7) C (2.5)
2026-10-22 C+ (2.5) D (1.3) C+ (2.8) B- (3.0) C+ (2.6) C (2.4)
2026-10-15 C+ (2.5) D (1.5) C+ (2.8) C+ (2.8) C+ (2.6) C (2.4)
Page 1 of 3